Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD

You don’t have permission to access “http://www.medpagetoday.com/meetingcoverage/ccc/114142” on this server. Reference #18.ade5c417.1739src87718.2src581b29 https://errors.edgesuite.net/18.ade5c417.1739src87718.2src581b29

You don’t have permission to access “http://www.medpagetoday.com/meetingcoverage/ccc/114142” on this server.

Reference #18.ade5c417.1739src87718.2src581b29

https://errors.edgesuite.net/18.ade5c417.1739src87718.2src581b29

Tama Howe

See author's posts

Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD

About Author

Tama Howe

Novo’s Weight Loss Drugs Removed from FDA Shortage List

‘Active recovery’ after exercise is supposed to improve performance—but does it really work?

Does Taking ‘The Pill’ Reduce Ovarian Cancer Risk?

Novo’s Weight Loss Drugs Removed from FDA Shortage List

‘Active recovery’ after exercise is supposed to improve performance—but does it really work?

The Surprising Source of Next-Gen Antibiotics: Oyster Blood

New GLP-1 Data Reinforce CV Benefit

Tool Predicts Whether One Bruise in Pediatric ED Signals Abuse

New lung scanning method can show treatment effects in real time

Engineering a smile: Stem cell–based conduits restore facial nerve function in animal study

10 FSA/HSA Eligible Fitness Items, Recommended by Our Editors

Engineered T cells could help patients overcome resistance to CAR T cell therapy

The 15 Best Beard Products for Men in 2025, Tested by Grooming Editors

Novo’s Weight Loss Drugs Removed from FDA Shortage List

‘Active recovery’ after exercise is supposed to improve performance—but does it really work?

The Surprising Source of Next-Gen Antibiotics: Oyster Blood

New GLP-1 Data Reinforce CV Benefit

Tool Predicts Whether One Bruise in Pediatric ED Signals Abuse

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories